AKT-Vimentin interaction; a potential role in soft tissue sarcoma progression and
AKT-波形蛋白相互作用;
基本信息
- 批准号:8458614
- 负责人:
- 金额:$ 29.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-01 至 2015-10-31
- 项目状态:已结题
- 来源:
- 关键词:AKT inhibitionAccountingAddressAdhesionsAffectAneuploidyApoptosisArchitectureAttentionAutomobile DrivingBackBehaviorBindingCarcinomaCell Cycle ArrestCell LineCell physiologyCellsChromosomal translocationClinicalComplexCytogeneticsDataDiseaseDistantEnvironmentEpithelialEtiologyFamilyGoalsGrowthHeterogeneityHistologyHumanHuman Cell LineImmigrationIn VitroInduction of ApoptosisIntermediate FilamentsInvestigationKaryotypeKnowledgeLaboratoriesLearningLungMalignant - descriptorMalignant Fibrous HistiocytomaMalignant NeoplasmsMesenchymalModelingMolecularMolecular ProfilingMusNeoplasm MetastasisOutcomePathway interactionsPatientsPhosphorylationPhosphotransferasesPreclinical TestingProcessPropertyProto-Oncogene Proteins c-aktRecurrenceRegulationResearchResistanceRoleSamplingSecondary toSignal PathwaySignal TransductionStructural ProteinTherapeuticTissuesTranslatingTumor MarkersUndifferentiatedVimentinXenograft ModelXenograft procedureabstractingbasecancer cellcell motilityepithelial to mesenchymal transitionfibrosarcomaimprovedin vivointerestleiomyosarcomamigrationmouse modelneoplastic cellnovelnovel therapeutic interventionoutcome forecastpre-clinicalprotein kinase C kinasesarcomasoft tissuestemtreatment centertumortumorigenic
项目摘要
Project Summary/Abstract
Soft tissue sarcomas (STS) constitute a family of mesenchymal -origin malignancies that
can occur anywhere in the body. Comprising more than 50 distinct histological subtypes,
STS share several distinctive features that include frequent local recurrence after
definitive therapy, marked chemoresistance, and frequent metastasis, especially to the
lungs. These features translate to a dismal outcome, especially for those patients
harboring high grade complex karyotype STS histologies, consisting mainly of
leiomyosarcoma and high grade pleomorphic sarcoma ( malignant fibrous histiocytoma
and fibrosarcoma). To improve STS therapeutic outcome it will be critical to develop
novel agents that capitalize on underlying STS points of molecular vulnerability;
however, progress towards this urgent goal are hampered by our minimal understanding
of the molecular determinants underlying STS prog ression and dissemination.
Tumor cells, including STS, respond to signaling cascades that control growth regulation
processes and other components of the malignant process such as motility, invasion,
induction of apoptosis, etc. Among theses signaling mechanisms, the AKT kinase
pathway may be particularly important in STS growth and dissemination.
Phosphorylation of AKT is a critical step in this cascade, had has been associated with
impaired STS prognosis when identified in STS tissues. In human STS cell lines and
human STS xenografts growing in immuno -incompetent mice, AKT inhibition interferes
with STS growth, perhaps by disrupting AKT interaction with vimentin, a critical
structural protein that may also have oncologically-relevant functional properties.
Our group is apparently the first to identify the existence of AKT -vimentin interactions.
We propose to study the regulation of this interaction, hoping to learn more about the
mechanisms underlying these interactions, the functional significance of this interaction
regarding how it impacts on STS proliferation and metastasis in vivo, and finally to test
preclinical therapeutic approaches to AKT and vimentin blockade, hoping to demonstrate
preclinical relevance using human STS xenograft mouse models and murine sarcoma
models.
项目总结/摘要
软组织肉瘤(STS)是一种间叶源性恶性肿瘤家族,
可以发生在身体的任何地方。包括50多种不同的组织学亚型,
STS有几个共同的特点,包括频繁的局部复发后,
明确的治疗,明显的化疗耐药性,和频繁的转移,特别是对
肺这些特点转化为一个令人沮丧的结果,特别是对那些病人来说,
具有高度复杂的核型STS组织学,主要包括
平滑肌肉瘤和高度多形性肉瘤(恶性纤维组织细胞瘤
和纤维肉瘤)。为了改善STS治疗结果,
利用分子脆弱性的潜在STS点的新型药物;
然而,由于我们缺乏理解,在实现这一紧迫目标方面进展受到阻碍
STS进展和传播的分子决定因素。
肿瘤细胞,包括STS,对控制生长调节的信号级联反应
过程和恶性过程的其他成分,如运动,侵袭,
在这些信号传导机制中,AKT激酶
途径可能在STS生长和传播中特别重要。
AKT的磷酸化是这一级联反应中的关键步骤,
当在STS组织中鉴定时,STS预后受损。在人STS细胞系中,
在免疫缺陷小鼠中生长的人STS异种移植物,AKT抑制干扰
随着STS的增长,也许是通过破坏AKT与波形蛋白的相互作用,
也可能具有肿瘤学相关功能特性结构蛋白。
我们的小组显然是第一个确定AKT -波形蛋白相互作用的存在。
我们建议研究这种相互作用的调节,希望更多地了解
这些相互作用的机制,这种相互作用的功能意义
关于它如何影响STS增殖和转移在体内,并最终测试
AKT和波形蛋白阻断的临床前治疗方法,希望证明
使用人STS异种移植小鼠模型和鼠肉瘤的临床前相关性
模型
项目成果
期刊论文数量(14)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Heterogeneity and immunophenotypic plasticity of malignant cells in human liposarcomas.
- DOI:10.1016/j.scr.2013.04.011
- 发表时间:2013-09
- 期刊:
- 影响因子:1.2
- 作者:Zhang, Yan;Young, Eric D.;Bill, Katelynn;Belousov, Roman;Peng, Tingsheng;Lazar, Alexander J.;Pollock, Raphael E.;Simmons, Paul J.;Lev, Dina;Kolonin, Mikhail G.
- 通讯作者:Kolonin, Mikhail G.
The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): a tissue microarray study.
c-Met 通路成分在未分类的多形性肉瘤/恶性纤维组织细胞瘤 (UPS/MFH) 中的表达:组织微阵列研究。
- DOI:10.1111/j.1365-2559.2011.03946.x
- 发表时间:2011
- 期刊:
- 影响因子:6.4
- 作者:Lahat,Guy;Zhang,Pingyu;Zhu,Quan-Sheng;Torres,Keila;Ghadimi,Markus;Smith,KerringtonD;Wang,Wei-Lien;Lazar,AlexanderJ;Lev,Dina
- 通讯作者:Lev,Dina
Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies.
- DOI:10.1371/journal.pone.0010105
- 发表时间:2010-04-16
- 期刊:
- 影响因子:3.7
- 作者:Lahat G;Zhu QS;Huang KL;Wang S;Bolshakov S;Liu J;Torres K;Langley RR;Lazar AJ;Hung MC;Lev D
- 通讯作者:Lev D
TNFα cooperates with IFN-γ to repress Bcl-xL expression to sensitize metastatic colon carcinoma cells to TRAIL-mediated apoptosis.
- DOI:10.1371/journal.pone.0016241
- 发表时间:2011-01-17
- 期刊:
- 影响因子:3.7
- 作者:Liu F;Hu X;Zimmerman M;Waller JL;Wu P;Hayes-Jordan A;Lev D;Liu K
- 通讯作者:Liu K
MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling.
- DOI:10.1158/0008-5472.can-11-3027
- 发表时间:2012-04-01
- 期刊:
- 影响因子:11.2
- 作者:Zhang P;Bill K;Liu J;Young E;Peng T;Bolshakov S;Hoffman A;Song Y;Demicco EG;Terrada DL;Creighton CJ;Anderson ML;Lazar AJ;Calin GG;Pollock RE;Lev D
- 通讯作者:Lev D
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MENASHE BARELI其他文献
MENASHE BARELI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MENASHE BARELI', 18)}}的其他基金
AKT-Vimentin interaction; a potential role in soft tissue sarcoma progression and
AKT-波形蛋白相互作用;
- 批准号:
8249120 - 财政年份:2009
- 资助金额:
$ 29.14万 - 项目类别:
Biology and Therapeutic Targeting of the Epidermal Growth Factor Receptor in Blad
Blad 表皮生长因子受体的生物学和治疗靶向
- 批准号:
7729507 - 财政年份:2008
- 资助金额:
$ 29.14万 - 项目类别:
Targeting Angiogenesis and the Tumor Microenvironment Utilizing si RNA
利用 si RNA 靶向血管生成和肿瘤微环境
- 批准号:
7895198 - 财政年份:2004
- 资助金额:
$ 29.14万 - 项目类别:
Targeting Angiogenesis and the Tumor Microenvironment Utilizing si RNA
利用 si RNA 靶向血管生成和肿瘤微环境
- 批准号:
8327828 - 财政年份:2004
- 资助金额:
$ 29.14万 - 项目类别:
Targeting Angiogenesis and the Tumor Microenvironment Utilizing si RNA
利用 si RNA 靶向血管生成和肿瘤微环境
- 批准号:
8728574 - 财政年份:2004
- 资助金额:
$ 29.14万 - 项目类别:
Targeting Angiogenesis and the Tumor Microenvironment Utilizing si RNA
利用 si RNA 靶向血管生成和肿瘤微环境
- 批准号:
8380914 - 财政年份:2004
- 资助金额:
$ 29.14万 - 项目类别:
BIOLOGY AND THERAPEUTIC TARGETING OF IL-8 AND MUC18/MCAM
IL-8 和 MUC18/MCAM 的生物学和治疗靶向
- 批准号:
6993431 - 财政年份:2004
- 资助金额:
$ 29.14万 - 项目类别:
Targeting Angiogenesis and the Tumor Microenvironment Utilizing si RNA
利用 si RNA 靶向血管生成和肿瘤微环境
- 批准号:
8541570 - 财政年份:2004
- 资助金额:
$ 29.14万 - 项目类别:
Malignant melanoma: Regulation by AP-2 and PAR-1
恶性黑色素瘤:AP-2 和 PAR-1 的调节
- 批准号:
8259480 - 财政年份:1999
- 资助金额:
$ 29.14万 - 项目类别:
Malignant melanoma: Regulation by AP-2 and PAR-1
恶性黑色素瘤:AP-2 和 PAR-1 的调节
- 批准号:
8065375 - 财政年份:1999
- 资助金额:
$ 29.14万 - 项目类别:
相似海外基金
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 29.14万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
- 批准号:
10100360 - 财政年份:2024
- 资助金额:
$ 29.14万 - 项目类别:
Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
- 批准号:
24K04974 - 财政年份:2024
- 资助金额:
$ 29.14万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
- 批准号:
23K01686 - 财政年份:2023
- 资助金额:
$ 29.14万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
- 批准号:
23K01692 - 财政年份:2023
- 资助金额:
$ 29.14万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
- 批准号:
23K01695 - 财政年份:2023
- 资助金额:
$ 29.14万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
- 批准号:
23K01713 - 财政年份:2023
- 资助金额:
$ 29.14万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
- 批准号:
2312319 - 财政年份:2023
- 资助金额:
$ 29.14万 - 项目类别:
Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
- 批准号:
23K01715 - 财政年份:2023
- 资助金额:
$ 29.14万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
- 批准号:
10585388 - 财政年份:2023
- 资助金额:
$ 29.14万 - 项目类别: